Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
Sodium Pertechnetate Tc-99m is a radioactive diagnostic imaging agent used for nuclear medicine procedures including thyroid, salivary gland, stomach, and blood pool imaging. It is a technetium-based radiopharmaceutical administered via injection or oral routes. The agent localizes to specific organs enabling visualization of structure and function for diagnostic assessment.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial teams should expect resource consolidation and transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Sodium Pertechnetate Tc-99m offers stability in a mature, diagnostic product portfolio but limited growth upside given LOE status and zero linked job openings. Career value lies in operational excellence, cost management, and regulatory/compliance expertise in radiopharmaceuticals rather than commercial expansion.
Worked on SODIUM PERTECHNETATE TC 99M at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.